A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Abstract excerpt

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Myeloma Research and Treatments
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Protein Degradation and Inhibitors